ES-SCLC treatment shifts towards double maintenance after 1L

12 Nov 2026
MIMS Editorial Team
MIMS Editorial Team
MIMS Editorial Team
MIMS Editorial Team
Dr Junko TanizakiDr Junko Tanizaki

In a clinical exchange session at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), Dr Junko Tanizaki of the Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai City, Osaka, Japan, discussed current first-line (1L) standards and evolving practice in extensive-stage small-cell lung cancer (ES-SCLC), highlighting a shift towards using two agents as maintenance following 1L chemo-immunotherapy (chemo-IO).

Chemo-IO + single-agent maintenance: IMpower133, CASPIAN

Chemo-IO followed by single-agent maintenance has become the established preferred 1L treatment for ES-SCLC on the basis of phase III IMpower133 and CASPIAN trials’ data. [NCCN Guidelines, Small Cell Lung Cancer, v1.2027] IMpower133, which compared atezolizumab plus carboplatin and etoposide (n=201) vs placebo plus carboplatin and etoposide (n=202), reported a median overall survival (mOS) of 13.9 vs 12.3 months (hazard ratio [HR], 0.70; 95 percent confidence interval [CI], 0.54–0.91; p=0.007) and a median progression-free survival (mPFS) of 5.2 vs 4.3 months (HR, 0.77; 95 percent CI, 0.62–0.96; p=0.02). [N Engl J Med 2018;379:2220-2229] At clinical cutoff, the 5-year OS rate was 12 percent in the atezolizumab arm. [Lung Cancer 2024;196:107924]

“While the standard works, only about one in eight patients are alive at 5 years,” noted Tanizaki.

In CASPIAN, the mOS was 12.9 months in the durvalumab plus platinum–etoposide group (n=268) vs 10.5 months in the platinum–etoposide group (n=269) (HR, 0.71; 95 percent CI, 0.60–0.86; p=0.0003), while 3-year OS rate was 17.6 vs 5.8 percent. [ESMO Open 2022;7:100408]

Chemo-IO + double-agent maintenance: IMforte, DeLLphi-303

The phase III IMforte trial evaluated the addition of lurbinectedin, a synthetic alkaloid derivative, to atezolizumab in the maintenance phase. Patients were initially treated with atezolizumab plus carboplatin and etoposide, and then randomized to receive both lurbinectedin and atezolizumab (n=242) or atezolizumab alone (n=241) as maintenance. At the clinical cutoff date (CCOD) of 29 July 2024, PFS, as assessed by an independent review facility, was longer in the lurbinectedin plus atezolizumab vs atezolizumab group (stratified HR, 0.54; 95 percent CI, 0.43–0.67; p<0.0001), as was OS (stratified HR, 0.73; 95 percent CI, 0.57–0.95; p=0.017). [Lancet 2025;405:2129-2143]

At the CCOD of 12 February 2025, the median investigator-assessed PFS was 5.6 vs 2.7 months (stratified HR, 0.56; 95 percent CI, 0.46–0.69) and mOS was 13.9 vs 11.1 months (stratified HR, 0.81; 95 percent CI, 0.65–1.01). [Paz-Ares L, et al, ESMO Immuno-Oncology 2025, abstract 245P] “The PFS benefit held, but the extent of OS benefit became less certain,” commented Tanizaki.

The addition of tarlatamab, a DLL3-directed bispecific T-cell engager IO, to an immune checkpoint inhibitor in the maintenance phase of ES-SCLC treatment was investigated in the phase Ib DeLLphi-303 study. Patients without disease progression after platinum–etoposide plus a PD-L1 inhibitor (if available) received tarlatamab with atezolizumab (n=48) or durvalumab (n=40) as maintenance until disease progression. The mPFS was 5.6 months in the tarlatamab plus atezolizumab group and 5.3 months in the tarlatamab plus durvalumab group. The respective mOS values were 25.3 months and not estimable. [Lancet Oncol 2025;26:1300-1311]

Take-home messages and remaining gaps

Chemo-IO plus single-agent maintenance remains the 1L standard of care, but its benefit is concentrated in a minority of patients.

Most advances in 1L practice are happening in the maintenance phase. The IMforte trial established the benefits of adding lurbinectedin to atezolizumab, and DeLLphi-303 reported an mOS of 25.3 months with tarlatamab plus a PD-L1 inhibitor.

“Three gaps remain: we cannot select patients by subtype, describe the risk in the patients we actually treat, and have no established treatment after durvalumab maintenance,” said Tanizaki. “Future advances in 1L SCLC treatment should involve both introducing new agents and determining which patients should receive them.”